Surrozen (SRZN) Stock Forecast & Price Target

Surrozen is viewed favorably because its lead retinal programs target a large unmet need with a differentiated Wnt-pathway strategy that is designed to restore vascular repair and reduce leakage, while SZN-8141 adds anti-VEGF activity that could improve translational relevance, efficacy, and adoption versus existing retinal therapies. The bullish thesis is reinforced by preclinical evidence of reduced nonperfusion and neovascularization, the supportive signal from Merck’s positive topline BRUNELLO data for Wnt agonism in diabetic macular edema, and the company’s expanding pipeline that includes SZN-8143 with additional IL-6 targeting and SZN-413 with IND-enabling GLP toxicology support from Boehringer Ingelheim’s milestone. Despite the 1Q26 net loss of $127.5M, the company held $106.9M in cash and equivalents as of March 31, 2026, and the stated path toward SZN-8141 IND submission anticipated 2H26 provides a concrete near-term catalyst for validating the platform in the clinic.

Surrozen is a clinical-stage biotechnology company with no approved products and limited near-term commercialization visibility, so its valuation remains highly dependent on successful execution of early-stage clinical programs rather than recurring revenue or operating scale. Although the recent read-through from Merck’s BRUNELLO data and the PTAB decision supporting Surrozen’s ‘278 patent are constructive, the core investment case still hinges on whether SZN-8141 can translate preclinical superiority into human efficacy in DME after the planned IND submission by the end of 3Q26 and Phase 1b/2a initiation by year-end 2026. The outlook is therefore negative because the company still faces substantial clinical, regulatory, and safety risk, while the field’s validation also highlights that meaningful efficacy, durability, and tolerability advantages must be proven in patients before the platform can justify durable value creation.